A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: SHR6390|DRUG: famitinib
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Collaborators: Jiangsu HengRui Medicine Co., Ltd.